Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021

Rhea-AI Summary

Reata Pharmaceuticals (NASDAQ: RETA) will report its third-quarter financial results and provide updates on development programs on November 8, 2021, pre-market. A conference call will take place at 8:30 a.m. ET the same day, with calls accessible for both domestic and international participants. The earnings press release will be available on the company’s website prior to the call. Reata focuses on developing novel therapeutics targeting cellular metabolism and inflammation, with investigational drugs bardoxolone methyl and omaveloxolone currently in clinical stages.

Positive

• Scheduled financial results announcement on November 8, 2021, indicating transparency and ongoing communication with shareholders.

Negative

• Bardoxolone and omaveloxolone are still investigational drugs, with their safety and efficacy not yet established, posing potential risks for investors.

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on November 8, 2021.

Reata’s management will host a conference call on November 8, 2021, at 8:30 a.m. ET. The conference call will be accessible by dialing (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) using the access code: 052919. The webcast link is https://event.on24.com/wcc/r/3408995/C86537D5F6ADF4E06CE5DB8BF34172CB.

Third quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the Company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005543/en/

Reata Pharmaceuticals, Inc.

(972) 865-2219

http://reatapharma.com

Investors:

Manmeet Soni

Andres Lorente

ir@reatapharma.com

media@reatapharma.com

https://www.reatapharma.com/contact-us/

Source: Reata Pharmaceuticals, Inc.

FAQ

When will Reata Pharmaceuticals report its financial results?

Reata Pharmaceuticals will report its financial results on November 8, 2021.

What time is the Reata Pharmaceuticals conference call?

The conference call will be held at 8:30 a.m. ET on November 8, 2021.

How can I access the financial results for Reata Pharmaceuticals?

The financial results will be available on Reata Pharmaceuticals' website shortly before the conference call.

What are the key drugs in development by Reata Pharmaceuticals?

Reata Pharmaceuticals' key drugs in development are bardoxolone methyl and omaveloxolone.